Literature DB >> 27121073

Gelsolin Promotes Radioresistance in Non-Small Cell Lung Cancer Cells Through Activation of Phosphoinositide 3-Kinase/Akt Signaling.

Ru-Sen Zhao1, Wei Wang1, Jun-Ping Li1, Chun-Mei Liu2, Liya He3.   

Abstract

Gelsolin is an actin-binding protein and acts as an important regulator of cell survival. This study aimed to determine the function of gelsolin in the radioresistance of non-small cell lung cancer cells. We examined the expression of gelsolin in radioresistant A549 and H460 cells and their parental cells. The effects of gelsolin overexpression and knockdown on the clonogenic survival and apoptosis of non-small cell lung cancer cells after irradiation were studied. The involvement of phosphoinositide 3-kinase/Akt signaling in the action of gelsolin was checked. We found that gelsolin was significantly upregulated in radioresistant A549 and H460 cells. Overexpression of gelsolin significantly ( P < .05) increased the number of colonies from irradiated A549 and H460 cells compared to transfection of empty vector. In contrast, knockdown of gelsolin significantly ( P < .05) suppressed colony formation after irradiation. Gelsolin-overexpressing cells displayed reduced apoptosis in response to irradiation, which was coupled with decreased levels of cleaved caspase-3 and poly adenosine diphosphate-ribose polymerase. Ectopic expression of gelsolin significantly ( P < .05) enhanced the phosphorylation of Akt compared to nontransfected cells. Pretreatment with the phosphoinositide 3-kinase inhibitor LY294002 (20 μmol/L) significantly decreased clonogenic survival and enhanced apoptosis in gelsolin-overexpressing A549 and H460 cells after irradiation. Taken together, gelsolin upregulation promotes radioresistance in non-small cell lung cancer cells, at least partially, through activation of phosphoinositide 3-kinase/Akt signaling.

Entities:  

Keywords:  gelsolin; lung cancer; radiotherapy; resistance; signaling pathway

Mesh:

Substances:

Year:  2016        PMID: 27121073      PMCID: PMC5616058          DOI: 10.1177/1533034616643884

Source DB:  PubMed          Journal:  Technol Cancer Res Treat        ISSN: 1533-0338


  31 in total

Review 1.  Cell signaling by receptor tyrosine kinases.

Authors:  J Schlessinger
Journal:  Cell       Date:  2000-10-13       Impact factor: 41.582

Review 2.  An overview of real-time quantitative PCR: applications to quantify cytokine gene expression.

Authors:  A Giulietti; L Overbergh; D Valckx; B Decallonne; R Bouillon; C Mathieu
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

3.  Stereotactic ablative radiotherapy and surgery: two gold standards for early-stage non-small cell lung cancer?

Authors:  Hanbo Chen; Alexander V Louie
Journal:  Ann Transl Med       Date:  2015-06

4.  Role of gelsolin in cell proliferation and invasion of human hepatocellular carcinoma cells.

Authors:  Biao Deng; JiaQing Fang; XiaoFei Zhang; Lei Qu; ZhongWei Cao; Bin Wang
Journal:  Gene       Date:  2015-07-03       Impact factor: 3.688

5.  Recombinant plasma gelsolin diminishes the acute inflammatory response to hyperoxia in mice.

Authors:  Melpo Christofidou-Solomidou; Arnaud Scherpereel; Charalambos C Solomides; Jason D Christie; Thomas P Stossel; Susan Goelz; Mark J DiNubile
Journal:  J Investig Med       Date:  2002-01       Impact factor: 2.895

Review 6.  Multifunctional roles of gelsolin in health and diseases.

Authors:  Guo Hua Li; Pamela D Arora; Yu Chen; Christopher A McCulloch; Peter Liu
Journal:  Med Res Rev       Date:  2010-11-09       Impact factor: 12.944

7.  Prognostic significance of gelsolin expression level and variability in non-small cell lung cancer.

Authors:  Jun Yang; Dongfeng Tan; Harold L Asch; Helen Swede; Gerold Bepler; Joseph Geradts; Kirsten B Moysich
Journal:  Lung Cancer       Date:  2004-10       Impact factor: 5.705

8.  Cell fate regulation by gelsolin in human gynecologic cancers.

Authors:  Mohammad R Abedini; Pei-Wen Wang; Yu-Fang Huang; Mingju Cao; Cheng-Yang Chou; Dar-Bin Shieh; Benjamin K Tsang
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-22       Impact factor: 11.205

9.  Gelsolin mediates collagen phagocytosis through a rac-dependent step.

Authors:  Pamela D Arora; Michael Glogauer; Andras Kapus; David J Kwiatkowski; Christopher A McCulloch
Journal:  Mol Biol Cell       Date:  2003-11-14       Impact factor: 4.138

10.  Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance.

Authors:  L Chang; P H Graham; J Hao; J Ni; J Bucci; P J Cozzi; J H Kearsley; Y Li
Journal:  Cell Death Dis       Date:  2013-10-24       Impact factor: 8.469

View more
  4 in total

1.  Inhibition of TDP43-Mediated SNHG12-miR-195-SOX5 Feedback Loop Impeded Malignant Biological Behaviors of Glioma Cells.

Authors:  Xiaobai Liu; Jian Zheng; Yixue Xue; Chengbin Qu; Jiajia Chen; Zhenhua Wang; Zhen Li; Lei Zhang; Yunhui Liu
Journal:  Mol Ther Nucleic Acids       Date:  2017-12-08       Impact factor: 8.886

Review 2.  Natural Polyphyllins (I, II, D, VI, VII) Reverses Cancer Through Apoptosis, Autophagy, Mitophagy, Inflammation, and Necroptosis.

Authors:  Bashir Ahmad; Yaser Gamallat; Muhammad Fiaz Khan; Syed Riaz Din; Muhammad Israr; Manzoor Ahmad; Naeem Tahir; Nasir Azam; Khalil Ur Rahman; Wang Xin; Wang Zexu; Peng Linjie; Pengyu Su; Wang Liang
Journal:  Onco Targets Ther       Date:  2021-03-10       Impact factor: 4.147

Review 3.  Current Landscape of Therapeutic Resistance in Lung Cancer and Promising Strategies to Overcome Resistance.

Authors:  Adnin Ashrafi; Zakia Akter; Pouya Modareszadeh; Parsa Modareszadeh; Eranda Berisha; Parinaz Sadat Alemi; Maria Del Carmen Chacon Castro; Alexander R Deese; Li Zhang
Journal:  Cancers (Basel)       Date:  2022-09-20       Impact factor: 6.575

4.  IL-11 mediates the Radioresistance of Cervical Cancer Cells via the PI3K/Akt Signaling Pathway.

Authors:  Ruige Sun; Chunli Chen; Xinzhou Deng; Fengqin Wang; Shimao Song; Qiang Cai; Jincheng Wang; Te Zhang; Mingliang Shi; Qing Ke; Zhiguo Luo
Journal:  J Cancer       Date:  2021-06-01       Impact factor: 4.207

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.